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Abstract
Background: The role of histocompatibility and immune recognition in stem cell transplant therapy has been controversial,
with many reports arguing that undifferentiated stem cells are protected from immune recognition due to the absence of
major histocompatibility complex (MHC) markers. This argument is even more persuasive in transplantation into the central
nervous system (CNS) where the graft rejection response is minimal.
Methodology/Principal Findings: In this study, we evaluate graft survival and neuron production in perfectly matched vs.
strongly mismatched neural stem cells transplanted into the hippocampus in mice. Although allogeneic cells survive, we
observe that MHC-mismatch decreases surviving cell numbers and strongly inhibits the differentiation and retention of
graft-derived as well as endogenously produced new neurons. Immune suppression with cyclosporine-A did not improve
outcome but non-steroidal anti-inflammatory drugs, indomethacin or rosiglitazone, were able to restore allogeneic neuron
production, integration and retention to the level of syngeneic grafts.
Conclusions/Significance: These results suggest an important but unsuspected role for innate, rather than adaptive,
immunity in the survival and function of MHC-mismatched cellular grafts in the CNS.
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Introduction
There is an ongoing controversy as to whether major
histocompatibility complex (MHC) matching is a significant
concern for stem cell grafts placed in the central nervous system
(CNS). The argument favoring the compatibility of unmatched
grafts is several fold. First, foreign tissue recognition in the CNS
does not elicit the same graft rejection response as observed in
peripheral tissues [1,2]. Second, MHC gene expression is low or
absent on many types of undifferentiated tissue stem cells,
including neural stem/progenitor cells (NPCs) [3,4]. Third, more
than 20 years of cellular transplant experience in humans
demonstrates that allogeneic cells can survive for decades in the
human brain without immune suppression [5,6]. These arguments
are not without merit and promising clinical studies are ongoing
using allogeneic cells or tissues to treat a variety of neurological
indications.
The underlying biology of cellular therapy is complex and the
emerging technology of autologous induced pluripotent stem cells
[7] demands a closer examination of allogeneic vs. autologous
cellular therapies. Neural transplantation studies have shown that
solid tissue grafts of allogeneic or xenogeneic origin elicit rejection
in the absence of immunosuppression [8]. This is due in part to the
presence of antigen presenting cells in the donor tissues, which
directly activate host lymphocytes by the ‘‘direct presentation’’
process [9]. In contrast, cellular grafts that lack donor-derived
vasculature and antigen presenting cells can avoid rejection in the
CNS [10,11,12]. These results suggest that highly purified cellular
allografts may have significant utility in the CNS. However, the
more subtle effects of MHC-incompatibility or the influence of
chronic immune activation that accompanies neural injury or
disease are not well defined.
Among the cell types considered for transplant therapy, NPCs
offer conceptual advantages in certain contexts. For example,
NPCs are able to differentiate into either neurons or glia and
earlier studies have shown that transplants of NPCs can
spontaneously generate neurons when introduced into sites of
native neurogenesis, such as the hippocampus or ventricular zone
[13,14,15]. In pediatric neuro-oncology, the inadvertent ablation
of native NPCs by chemotherapy [16] or radiation [17,18] is
suspected to cause a delayed yet progressive cognitive decline that
can become debilitating as children reach adulthood. NPC
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following cancer treatment and attenuate these cognitive side
effects of cancer therapy. However, our earlier work has
highlighted the negative impact of proinflammatory signaling on
postnatal and adult neurogenesis [18] and this has brought out
attention to the potentially important but unexplored role of
immune signaling following mismatched vs. perfectly matched
NPC transplants. In the present study, our goals were to determine
if MHC matching within an otherwise un-manipulated and
healthy neurogenic zone of the hippocampus would alter the
ability of transplanted NPCs to populate the endogenous neural
stem cell pool and contribute to the ongoing production of
neurons.
Results
MHC Disparity between C57BL/6 and Balb/c Mice
Induces Strong Allogeneic Responses
We chose two inbred strains of mice that are strongly divergent
at the mouse H2 MHC locus for this analysis. To confirm that the
mismatch between Balb/c (H-2
d) and C57BL/6 (H-2
b) mice were
sufficient to elicit strong allogeneic responses, reciprocal hetero-
topic cardiac allograft transplantation [19] between the two strains
was performed. Consistent with previous reports [19,20], allograft
resulted in rapid and complete rejection indicating a pronounced
immunological disparity (Fig. S1A, mean day until rejection =
8.7560.75, C57BL/6-.Balb/c; 8.2560.25, Balb/c-.C57BL/6).
In contrast, isogenic grafts between BALB/c donors and
recipients, or between C57Bl/6 donors and recipients, had long
term survival (.30 days). This confirmed that the two strains
chosen elicit strong reciprocal allograft responses to solid tissue
grafts. In addition, splenocytes were isolated from each strain and
cultured in standard one-way mixed lymphocyte response (MLR).
As expected, mitomycin C-inactivated C57BL/6 splenocytes
induce robust proliferation of Balb/c splenocytes (Fig. S1B).
MHC Expression in NPCs
We next examined the MHC and co-stimulatory molecule
expression on C57BL/6 and Balb/c NPCs by flow cytometry.
NPCs were cultured and propagated in vitro as neurospheres and
evaluated at passage 10. As others have reported [3,21],
undifferentiated NPCs exhibited no MHC class I or class II
expression but did show low levels of CD80 co-stimulatory
molecule expression (Fig. S2). Cells were negative for co-
stimulatory molecules CD40 and CD86 (Fig. S2). To determine
if NPCs can provoke lymphocyte proliferation, C57BL/6
splenocytes were cultured with mitomycin C-inactivated
C57BL/6 or Balb/c NPCs. Consistent with the lack of MHC
expression, a proliferative splenocyte response was not detected
after 48 hrs (not shown). However, after 5 days in mixed culture,
allogeneic NPCs were able to induce a delayed low-level
lymphocyte proliferation while isogenic NPCs did not (Fig. S2B),
in agreement with previous report [22].
To determine if proinflammatory cytokines that might be
encountered in a transplant context alter MHC expression, NPCs
were exposed to 30 ng/ml of TNFa, IL-1b, IL-6 or IFN-c for
72 hrs and re-evaluated for the MHC and co-stimulatory molecule
expression. MHC I and MHC II expression were mildly
upregulated by TNFa treatment. IFN-c treatment strongly
augmented MHC I and moderately enhanced MHC II expression;
whereas IL-1b and IL-6 showed little effect on MHC expression
(Fig. S2C). CD80 expression was enhanced by TNFa, IL-1b, and
IFN-c but not IL-6. None of the four cytokines tested showed
effect on the expression of CD40 or CD86.
Graft Survival and Neuron Production is Reduced in
Mismatched vs. Matched NPCs
NPCs were isolated from GFP transgenic mice as described in
methods and propagated as neurospheres [23]. Single cell
suspensions were prepared and introduced by stereotaxic injection
into the dentate gyrus (DG) of wild type C57BL/6 or Balb/c mice.
NPCs were also injected into the DG of C57BL/6 Krt1-15-GFP
mice which natively express GFP in cells of the hair follicle [24].
Two weeks or one month later, the mice were perfused and brains
evaluated by immunostaining to characterize the survival and fate
of the grafted cells.
Consistent with prior studies [17,18], a bolus of donor cells was
observed at the injection site within the DG. Many cells had
migrated from the injection site to populate the neighboring
subgranular zone and granular cell layer (Fig. 1). The number and
maturation state of graft-produced neurons was scored within the
DG by fluorescent immunostaining for GFP and NeuN at two
weeks or one month after transplantation. The number of
surviving NPCs was quantified using unbiased stereology and
the fraction of NPCs adopting a neuronal fate estimated by
confocal co-localization of GFP with the mature neuronal marker
NeuN.
At two weeks after transplant, the number of surviving cells was
reduced by approximately 75% in allografts relative to isografts
(Fig. 1A). Within the surviving population, the fraction of cells that
had differentiated into neurons (NeuN+) was also reduced by
approximately 90% in the allograft group relative to the isograft
group (Fig. 1B). At one month after grafting, the survival rate and
the fraction of NeuN+ cells did not significantly differ from the 2
week time point (Fig. 1C, D). As expected, the fraction of cells
expressing the mature neuronal marker NeuN showed a small
increase in both syngeneic and allogeneic grafts, consistent with
more of the transplanted cells maturing to express NeuN at 4
weeks after transplant (p=0.08 and 0.28 for the comparison for
NeuN% from isograft and allograft at 2 vs. 4 wk, respectively).
This data indicates that the effects of the MHC disparity between
donor and recipient primarily influence outcome in the initial two
weeks following transplant. Isograft survival and the abundance of
neurons was not significantly different between wild type C57BL/
6 and C57BL/6 Krt1-15-GFP mice that express an endogenous
GFP in skin keritinocytes indicating that immune recognition of
GFP was not a significant factor in these studies (not shown).
Microglia are Activated to a Higher Extent in Mismatched
vs. Matched Transplants
As others have reported, host microglia are activated and
phagocytize dying cells following cell transplant [25]. To evaluate
microglial activation two weeks after transplant, tissues were
stained for Iba-1, a general marker for microglia and macrophages
[26] and for CD-68, a marker that is upregulated following
monocyte activation [27]. The relative tissue area positive for Iba-
1 staining significantly increased in allografts relative to isografts
(Fig. 2), suggesting an increase in microglial numbers and/or
activation-related microglial hypertrophy. The pixel abundance of
CD68 was also strongly elevated in allografts, indicating a more
pronounced or prolonged microglial response relative to the
response elicited by isografts.
To evaluate class I MHC expression in transplanted NPCs,
tissues were stained with H-2K
b selective antibodies which
recognize alleles expressed by C57B/6 but not Balb/c mice. H-
2K
b staining following C57B/6 NPC transplant into either Balb/c
(allografts) or C57B/6 (isografts) mice shows a strong increase in
local K
b staining in both allo and isograft contexts (Fig S3). The
Mismatch Inhibits Neurogenesis
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like morphology. H-2K
b is low in GFP-marked NPC surviving at
the 2 wk time point and the intensity of staining is not obviously
different in C57B/6 NPCs surviving in the isograft or allograft
contexts. H-2K
b staining in Balb/c microglia (which are H-2K
d
haplotype) is consistent with expression of class I MHC in NPCs
following transplant with phagocytosis of cell debris and
presentation of NPC antigens by host microglia/monocytes.
Mismatch-Induced Signaling Inhibits Endogenous
Neurogenesis
We have previously shown that microglial proinflammatory
signaling inhibits native neurogenesis in the DG [18], so we sought
to determine whether the inflammatory response to allografts also
decreases endogenous neurogenesis in the DG. To label
endogenously dividing progenitor cells, C57BL/6 mice were
injected with BrdU once each day for 6 days prior to NPC
transplant. GFP-expressing C57BL/6 and Balb/c NPCs were then
stereotaxically introduced into the DG. Brains were analyzed two
weeks later by immunostaining for the survival and differentiation
of the BrdU-labeled endogenous NPCs (Fig. 3).
As newborn neurons mature, they initially express doublecortin
(Dcx) and then gradually begin to express NeuN. Ultimately Dcx
expression is extinguished in mature NeuN+ neurons. The relative
numbers of BrdU-labeled cells that are positive for Dcx alone,
Dcx+NeuN, or NeuN alone provides an indication of the rate
and/or efficiency at which newborn neurons mature and survive
over a given period of time. The fraction of immature (Dcx+),
transitional (Dcx+NeuN+) and mature (NeuN+) neurons derived
from endogenous NPCs were reduced in mice receiving allograft
by roughly 32%, 76% and 47%, respectively (Fig. 3A).
An evaluation of glial markers showed that the reduction in
neurogenesis in the allograft transplant environment was accom-
panied by an increase in the fraction of cells adopting glial fates.
The percentages of BrdU+ astrocytes (GFAP) and oligodendrocyte
Figure 1. Survival and neuron production is reduced in allografts. C57BL/6 GFP-positive NPCs were transplanted into C57BL/6 or Balb/c
mice. Two weeks or one month later, brains were harvested and analyzed for survival and differentiation of the grafts. (A–D) The number of surviving
cells per DG and the proportion of these cells expressing a mature neuronal marker (NeuN+) were scored. Survival and neuron production were
significantly lower in allografts. * p,0.05, n=5, compared with isografts. (E–G) Representative pictures of isograft (E), allograft (F) and mature NeuN+
neurons derived from NPC grafts (G). Green, GFP; Red, NeuN; Blue, Dcx. Scale bars, 100 mm (E and F) and 10 mm (G). For all figures in this study, S.E.M
is indicated by error bars.
doi:10.1371/journal.pone.0014787.g001
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(Fig. 3B). The survival of endogenous NPCs labeled prior to the
transplant was also reduced in mice receiving allograft vs. isograft,
as indicated by a reduction in the total number of BrdU+ cells
within the DG (Fig. 3C).
Treatment with NSAIDs but not Cyclosporine-A Restores
Neuron Production
Cyclosporine-A (CsA) is a drug typically used to immunosup-
press transplant patients and primarily targets T cell activation
through inhibition of calcineurin signaling [28]. We have also
previously observed that the non-steroidal anti-inflammatory drug
(NSAID) indomethacin is able to restore endogenous neurogenesis
after an innate immune activation [18]. Here we have evaluated
three drugs, CsA, indomethacin, and rosiglitazone, for their
potential to prevent allograft effects in the NPC transplant model
(Fig. 4). Drugs were administered starting two days prior to
transplant of GFP-expressing NPCs into allogeneic and isogenic
hosts. CsA was administered by daily intraperitoneal (i.p.) injection
and indomethacin and rosiglitazone were provided orally in
flavored food treats. Treatment continued for two weeks at which
time brains were evaluated for cell survival and the abundance of
graft-derived neurons. CsA dosing regimes that we have previously
optimized to prevent xenograft rejection [29] did not significantly
Figure 2. Elevated microglial activation in allografts. Following NPC transplantation, host microglia were stained for Iba-1 and CD68. (A, B)
Iba-1 and CD68 staining increased in allografts relative to isografts indicating an increase in the number and/or hypertrophy of microglia or monocyte
lineage cells (*p,0.05, n=5). (C–F) Representative fluorescent confocal micrographs of isografts (C,E) and allografts (D,F). Iba-1 green in C and D;
CD68 red in E and F. Scale bars, 20 mm (C and D) and 50 mm (E and F).
doi:10.1371/journal.pone.0014787.g002
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rosiglitazone treatment increased cell survival and the abundance
of neurons in allografts to levels observed in isografts (Fig 4A and B).
To determine if drug treatment also influenced endogenous
neurogenesis, the total number of GFP-negative Dcx-positive (i.e.,
endogenous immature neurons) was scored. The reduction in the
abundance of Dcx-positive neurons that normally accompanies
allografts was unaffected by CsA but attenuated by treatment with
indomethacin or rosiglitazone (Fig. 4C). An evaluation of the pixel
abundance of CD68 within the DG revealed that microglia activation
was also mitigated by treatment with NSAIDS but not CsA (Fig. 4D).
The efficacy of NSAIDs but not CsA was unexpected since
antigen presentation and T cell activation is thought to be central
to allograft recognition. To determine if there were differences in
lymphocyte infiltration into the transplant site of control or drug-
treated animals, the numbers of CD4+ and CD8+ T cells within
the hippocampus were estimated using unbiased stereology. T cells
were detected in both isograft and allograft contexts. There was no
significant difference in the abundance of CD4-positive T cells
between isografts and allografts. The mean number of CD8+ T
cells was higher in the allograft control group, and while this may
indicate allo-selective differences in the abundance of cytotoxic T
cells, the differences did not reach statistical significance,
suggesting that allo-specific T cell recruitment and amplification
may not be the central mediator of the effects noted in the current
experimental context (Fig. S4).
Intra-hippocampal Grafting of Allogeneic NPCs does not
Prime Lymphocytes in the Host
Given the presence of T cells and the physical breakdown of the
blood brain barrier from the cell injection itself, it was possible that
allo antigen recognition was sufficient to prime a systemic immune
response and that later analysis of mixed lymphocyte reactions
would reveal the earlier exposure to allo antigens. Splenocytes
were isolated one month after NPC transplant and cultured in vitro
with mitomycin C-treated Balb/c or C57BL/6 splenocytes as
stimulator cells. 72 hrs later, proliferation was determined by
incorporation of
3H thymidine. Splenocytes from mice receiving
isograft vs. allograft NPCs did not differ in the capacity to respond
to allogeneic lymphocyte stimulation, confirming that T cell
responses were localized to the transplant site and were not
sufficient to elicit systemic priming in the host [3,4] (Fig. S5).
NSAIDs Treatment Modifies Graft-induced Cytokine
Profiles in the Hippocampus
To further understand the potential basis of the allograft effects
and their attenuation by NSAIDs, isografted and allografted mice
were treated with vehicle or NSAIDs and then hippocampal
tissues isolated and protein extracts prepared 48 hrs after
transplantation. Tissue extracts were evaluated by Luminex 25-
plex cytokine assays. The allografts showed significantly higher
levels of proinflammatory cytokine production overall (p,0.05 for
genotype, two way ANOVA). When individually evaluated, 14 of
the 25 tested cytokines showed significant upregulation by T-test,
including eotaxin (CCL11), G-CSF, GM-CSF, TNFa, IL-12p70,
IL-13, IL-1b, KC (CXCL1), MCP-3 (CCL7), MIP-1a (CCL3),
RANTES (CCL5), IL-23, IL-12p40 and IP-10 (CXCL10) (Fig. 5A
and B). No significant difference was observed for the remaining
cytokines tested (Fig. S6). Treatment with either indomethacin or
rosiglitazone significantly reduced the cytokine production in the
allograft group (p,0.05 for treatment, two way ANOVA). Of
those cytokines affected by NSAIDs, TNFa, IL-1b, IL-12p70, IL-
Figure 3. Allograft-induced signaling blocks endogenous neurogenesis and favors glial production. C57BL/6 mice were given one i.p.
BrdU injection daily for 6 consecutive days followed by transplantation of isogenic or allogeneic NPCs on day 7. Two weeks after transplantation,
brains were harvested and examined for cell-type specific markers in the endogenous BrdU-labeled progenitors. (A,B) the percentage of cells staining
positive for each marker or markers was quantified. Fewer immature (Dcx+ alone), transitional (Dcx+/NeuN+) and mature (NeuN+ alone) neurons but
more GFAP+ astrocytes and NG2+ oligodendrocytes derived from endogenous NPCs were observed in allograft vs. isograft group. * p,0.05;
# p,0.1, n=4, compared to isograft. (C) The total number of BrdU-labeled endogenous NPCs at the DGs per mouse was scored. Significantly fewer
BrdU+ endogenous NPCs were found in allograft vs. isograft groups, (* p,0.05, n=4). (D–G) Representative pictures of Dcx (D), NeuN (E), GFAP (F)
and NG2+ (G) cells differentiated from BrdU-labeled endogenous NPCs. Red, BrdU; Yellow, NeuN; blue, DAPI; white, Dcx (D and E), GFAP (F) or Ng2 (G).
Scale bar, 10 mm.
doi:10.1371/journal.pone.0014787.g003
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in both indomethacin- and rosiglitazone-treated allograft groups
(Fig. 5C and D). For the indomethacin allograft group (but not
rosiglitazone), GM-CSF level was also significantly decreased and
the expression of IL-12p40, IP-10, RANTES, KC, G-CSF and IL-
17 showed a trend of down regulation. Rosiglitazone treatment
(but not indomethacin) significantly reduced the production of IL-
12p40, IP-10, RANTES, KC and IL-23 (Fig. 5E and F). The
overlapping but non-identical effects on cytokine profiles for these
two drugs is in keeping with their known target spectrum and
suggests that those cytokines most robustly reduced by either
NSAID may be responsible for the allograft effects. These would
include TNFa, IL-1b, IL-12p70, IL-13, MIP-1a and MCP-3.
Discussion
CNS allografts have long been considered for treatment of
neurological disease and there is extensive evidence that allografts
can survive in the CNS without long-term immunosuppression;
however, how tissue mismatch might affect outcome in other ways
is not clear. We have found that allogeneic transplants elicit
immune signaling in the brain which detrimentally affects NPC
survival and selectively impairs the production of neurons. These
effects appear to occur during the first weeks following transplant
and can be prevented by short courses of NSAID administration
but not by immunosuppression using CsA.
In humans, allogeneic cell transplants almost invariably include
a short course of immunosuppression (most commonly CsA) to
minimize chances of graft rejection through a T-cell-mediated
adaptive immune response [28,30]. We did not detect any
significant changes in the behavior of isografts, allografts, or
endogenous progenitors following CsA treatment in vivo (Fig. 4). In
contrast, we have shown in prior work that the NSAIDs can
attenuate the negative effects of innate proinflammatory signaling
on hippocampal neurogenesis [18] and find here that a broad
spectrum NSAID, indomethacin, or the more selective PPAR-c
activator rosiglitazone can promote the production and/or
survival of neurons produced by transplanted NPCs.
Steroidal anti-inflammatory drugs are commonly used in
neural transplantation. Although effective, such drugs were not
considered here due to the known suppressive effects of adrenal
steroids on adult neurogenesis [31,32]. As a potential substitute,
NSAIDs such as indomethacin also have good CNS penetration
and act by attenuating innate proinflammatory signaling through
inhibition of Cox1/Cox2 and activation of PPAR-c [33,34].
Unfortunately, like CsA or steroidal anti-inflammatory drugs,
indomethacin also has unwanted side effects at doses sufficient to
attenuate inflammation in the CNS. In contrast, rosiglitazone, a
non-classical NSAID that has shown promise as an immuno-
modulatory drug in the clinical treatment of Alzheimer’s disease
[35], is well tolerated over long periods and was equally effective
as indomethacin at reversing allograft-specific impairment in
neurogenesis.
The effectiveness of rosiglitazone in overcoming an allograft-
selective loss of neurons provides several intriguing leads into the
mechanisms that may be responsible. Rosiglitazone selectively
activates PPAR-c which consequently alters expression of genes
regulated by PPAR-c There are roughly 100 known targets,
among which are numerous proinflammatory cytokine genes [36].
Our cytokine expression data confirms that rosiglitazone attenu-
ates proinflammatory cytokine response elicited by allografts.
While speculative, it seems reasonable to predict that cytokines
Figure 4. Treatment with NSAIDS restores neuron production in allografts. C57BL/6 GFP-positive NPCs were transplanted into C57BL/6 or
Balb/c mice. Mice were administered NSAIDS (indomethacin or rosiglitazone), immunosuppressant CsA, or vehicle starting 2 days prior to transplant
and continuing for two week after transplant, at which time mice were sacrificed and brains harvested. (A) Total number of GFP-positive cells was
counted using unbiased stereology. The number of surviving GFP-positive cells was significantly reduced in non-treated allografts compared with
non-treated isografts. Treatment with indomethacin and rosiglitazone but not CsA significantly enhanced graft survival. (B) The percentage of GFP-
positive cells that turn into mature neurons (NeuN+) was lower in allografts vs. isografts. Neuron production was significantly increased by NSAID
treatment but not CsA. (C) The number of endogenous neuron precursor cells (Dcx-positive and GFP-negative) located at the DG was counted using
unbiased stereology. Indomethacin and rosiglitazone but not CsA treatment significantly augmented the number of Dcx+ cells. (D) CD68 expression
was used to quantify microglial activation. Untreated allografts show significant increase in CD68 immunoreactivity compared to untreated isografts.
Treatment with NSAIDS but not CsA suppressed microglia activation (* p,0.05, n=4–5).
doi:10.1371/journal.pone.0014787.g004
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rosiglitazone may be relevant to the allo-specific impairment in
neuron production or survival. Among these are TNFa and IL-1b,
both important early mediators of the acute innate proinflamma-
tory response that triggers subsequent lymphocyte infiltration,
antigen presentation, and initiation of the adaptive response. In
vitro, both cytokines have been shown to directly attenuate
neurogenesis in NPCs [37,38]. The other four cytokines/
chemokines that have been down regulated by both indomethacin
and rosiglitazone are IL-12, IL-13, MIP-1a and MCP-3. It is still
unknown whether any of these cytokines has direct effect on
grafted or endogenous NPCs and future studies are needed to test
it. IL-12, MIP-1 and MCP-3 are all pro-inflammatory cytokines
which play important role in the regulation of macrophage/
microglia activation and migration. It is possible that NSAIDs may
work in the present model by simply attenuating proinflammatory
cytokine expression following activation of the acute innate
immune response.
We have confirmed that purified NPCs in vitro do not express
MHC I or MHC II and it seems unlikely that infiltrating T cells
would be strongly activated by presentation of allo-specific MHC.
However, the cytokines produced acutely in response to the
injection injury (or that may be present due to a disease or injury
present in a transplant context) may upregulate NPC MHC
expression, as seen in vitro (Fig. S2C). This may be sufficient to
initiate a recognition response in vivo. MHC I expression was low
in surviving NPCs but also detected in host microglia and
macrophages. This is consistent with an upregulation of MHC
following exposure to cytokines in the graft with phagocytosis and
re-presentation of allo-MHC by host microglia and macrophages
(Fig. S3). This should provide an effective context for the
recruitment of allo-specific T cells. Although T cells are present
in the grafts, CsA failed to alter outcome and we conclude that
classical calcineurin-dependent T cell activation, amplification and
lysis of NPCs is unlikely to account for all of the effects.
Furthermore, the endogenous neural progenitors would not be
recognized by allo-reactive T cells yet they are equally inhibited in
the production and survival of neurons in the allograft environ-
ment. While this argues against T cell specific lysis of allogeneic
neurons, it does not completely exclude a role for T cells. It is
possible that allogeneic grafts do trigger a larger number of
infiltrating cells during the earliest stages of innate immune
activation and antigen presentation. Cytokines acutely released by
these cells (including T cells) may reinforce or amplify microglial
Figure 5. Treatment with NSAIDs Attenuates Cytokine Production in the Hippocampus. The hippocampi of isografted and allografted
mice treated with or without NSAIDs were dissected 48 hrs after transplantation and protein extracts evaluated by Luminex 25-plex cytokine assay.
(A,B) 14 of the 25 tested cytokines showed significant upregulation, including eotaxin, G-CSF, GM-CSF, TNFa, IL-12p70, IL-13, IL-1b, KC, MCP-3, MIP-
1a, RANTES, IL-23, IL-12p40 and IP-10. (C,D) Treatment with indomethacin or rosiglitazone significantly reduced the cytokine production in the
allograft group, including TNFa, IL-1b, IL-12p70, IL-13, MIP-1a and MCP-3. (E,F) After indomethacin treatment, GM-CSF was also significantly
decreased and the expression of IL-12p40, IP-10, RANTES, KC, G-CSF and IL-17 showed a trend towards down regulation. Rosiglitazone treatment also
significantly reduced the production of IL-12p40, IP-10, RANTES, KC and IL-23. * p,0.05, # p,0.1, n=5–6.
doi:10.1371/journal.pone.0014787.g005
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factors in the CNS attenuate subsequent steps of the adaptive
response and prevent a classical CsA-sensitive T cell amplification
and cytolytic graft rejection. The presence of CD4 and CD8 cells
at the transplant site (Fig. S4) confirms that T cells are present and
suggests a degree of T cell response from the host, possibly
mediated by elevated CD8-positve cells. However, cell survivals at
2 weeks and 4 weeks were not different and inhibition of T cell
receptor signaling with CsA did not significantly alter outcome. It
seems likely that allograft-induced upregulation of cytokines or
chemokines may play a relatively important role in the observed
inhibitory effect of allografts on neuron production and survival in
the context of the present studies.
It is clear from earlier work that intracerebral allografts show
good long-term survival when transplanted into the striatum [40].
However, the graft can be recognized and eliminated by a classical
allograft response, particularly when the animal has been primed
with a peripheral allograft [40,41]. It is possible that hippocampus
is a special target site close to the ventricles and therefore more
prone to immunological effects than other target areas such as the
striatum [42], which may account for the observed reduction in
survival of allograft vs. isograft in our work relative to results seen
in striatal grafts [40]. However, if this response is incrementally
larger in the hippocampus, it is still not sufficient to cause systemic
priming [43]. Splenocytes from transplanted animals show no
evidence of prior exposure to allo antigens (Fig. S5). This does not
eliminate a role for T cells but does confirm that the local allo-
specific T cell response is not sufficiently strong to elicit systemic
immunity. Instead, we find evidence that innate immune signaling
and related cytokine signaling may play a larger role.
The mechanism underlying the selective upregulated cytokine
production by allo- vs. isografts is unclear but it is possible that
these influences may stem from the signaling networks mediated
by many immune cell types, including microglia, and infiltrating
lymphocytes such as T cells, NK and/or NK-T cells. Reduced
cytokine abundance may attenuate many of the subsequent innate
and adaptive responses in the host, including T-cell relevant
processes of antigen presentation and expression of co-stimulatory
molecules. It is also possible that NSAIDs act directly on neural
progenitor cells to promote neurogenesis but we have not been
able to detect differences in endogenous neurogenesis when these
drugs are administered to naı ¨ve animals. This suggests that the
primary mechanisms are related to cytokine production and/or
modulating cytokine response in the host and graft.
CsA was surprisingly ineffective but this result is consistent with
earlier studies evaluating allogeneic cell survival in the presence or
absence of CsA [44,45]. These studies have led to a general
assumption in the field that allogeneic mismatch may not be
relevant in neural transplantation because cell survival is similar in
the presence or absence of CsA. In our model, even cells carrying
the xenotypic jellyfish GFP protein had equivalent survival rates in
wild type hosts and in congenic hosts where endogenously
expressed GFP would not be a ‘‘foreign’’ protein. This highlights
the relative tolerance of the brain to foreign tissues yet strengthens
the importance of recognizing and understanding the more subtle
immune-brain interaction that revolves around innate immune
response and elaboration of proinflammatory cytokines. Although
promising, care should be taken in interpreting our results using
NSAIDs. The current study focused on the early post-graft period
and did not include time points beyond 4 weeks. The chronic
effects of both major and minor histocompatibility mismatch have
not been fully addressed in the short time frames of the present
study and it is possible that drugs such as CsA or adrenal steroids
are indeed important in long-term outcome. However, the present
study does draw our attention to the unexpected utility of non-
steroidal immunomodulatory drugs that attenuate innate immune
signaling and cytokine release triggered by transplantation.
Together, the results confirm prior work that strongly mismatched
allogeneic neural stem cell grafts can survive in the absence of
immune suppression. However, it is also clear that histocompat-
ibility does impact cell survival in this model and has a strongly
selective effect on the abundance of graft-derived new neurons.
Non-traditional immunomodulatory drugs, such as NSAIDs, may
be valuable adjunct treatments for improving transplant survival in
the CNS and promoting the therapeutic integration and retention
of graft-derived neurons.
Materials and Methods
Ethics Statement
All animal protocols used in the present study were reviewed
and approved by the Administrative Panel on Laboratory Animal
Care (APLAC) at Stanford University, APLAC approval number:
10362.
Mixed Lymphocyte Assay
C57BL/6 (H-2
b) or Balb/c (H-2
d) splenocytes (1610
6/ml) were
co-cultured with mitomycin C-treated isogenic or allogeneic
stimulator splenocytes (1610
6/ml, either on C57BL/6 or Balb/c
background). Cells were pulsed after 3 or 5 days in culture with
0.5 mCi H
3 and were harvested and analyzed 18 hours later. In
Mixed NPC Lymphocyte assay, C57BL/6 splenocytes (1X10
6/ml)
were co-cultured with mitomycin C-treated C57BL/6 or Balb/c
NPCs at varying ratios. Cells were pulsed after 5 days in culture
with 0.5 mCi H
3 and were harvested 18 hours later. The
stimulation index scores were generated by calculating the ratio
of thymidine incorporation in experimental groups compared to
the incorporation in control splenocytes without stimulators.
Cardiac Transplantation
Vascularized heterotopic cardiac transplantations were per-
formed by standard microsurgical techniques and Balb/c (H-2
d)
mice were grafted with C57BL/6 (H-2
b) hearts or C57BL/6 (H-
2
b) mice were grafted with Balb/c (H-2
d) hearts according to the
method of Corry [46]. Transplanted hearts were monitored daily
by palpation through the abdominal wall in a blind fashion and
assigned a score ranging from 0–4, with 4 representing a perfectly
contracting heart and 0 representing the cessation of beating.
Neural Progenitor Cell (NPC) Culture
NPCs were isolated from P0 pups of wild type Balb/c, wild type
C57BL/6 (The Jackson Laboratory, Bar Harbor, Maine) or
C57BL/6 CAG/GFP transgenic mice [47] (kindly provided by the
laboratory of Irving Weissman). Using methods previously
described [18], the cerebellum and brain stem were removed
from whole brains of neonatal animals and the remaining tissues
enzymatically digested with a mixture of papain, neutral protease,
and DNAse and the debris removed by discarding the supernatant
from a 25% Percoll fractionation. Neurospheres were cultured
with medium containing Neurobasal A (Gibco, Grand Island,
NY), L-glutamine, penicillin, streptomycin, fungizone, B-27
without vitamin A, 20ng/ml fibroblast growth factor-2 (FGF-2),
and 20 ng/ml epidermal growth factor (EGF) (Invitrogen,
Carlsbad, CA). Cells were passaged by dissociation with
Trypsin/DNAse (Worthington Biochemical Corp., Lakewood,
NJ) followed by re-plating in growth medium. Where indicated,
wild type C57BL/6 or Balb/c NPCs were labeled with GFP via
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lentivirus FUGW [48].
To ensure that the intrinsic differentiation profiles of NPCs from
each mouse strain cells were similar, neurospheres were dissoci-
ated and cultured under differentiating conditions that promote
the accumulation of both neurons and glia [49]. After 5 days, cells
were fixed and stained for the immature neuron marker Dcx, the
astroglial marker glial fibrillary acidic protein (GFAP), and the
NG2 proteoglycan, a marker expressed by immature oligoden-
drocytes. There were no significant differences in the fraction of
each cell type produced indicating that cultures from both mouse
strains were roughly equivalent in their native differentiation
profiles (Fig. S7).
Flow Cytometric Analysis of NPCs
Neurospheres were dissociated and plated onto poly-ornithine/
laminin-coated plates and then passaged once to obtain a
monolayer (poly-ornithine from Sigma and laminin from
Invitrogen). TNFa, IL-1b, IL-6 or IFN-c (all from Peprotech,
Rocky Hill, NJ) was added to the growth medium at 30 ng/ml for
72 h. Cells were collected from the dishes by enzymatic treatment
and washed once in BSA/PBS and stained with FITC-, PE- and
PECy5-conjugated antibodies against CD40, CD80, CD86, MHC
II (all obtained from eBioscience, San Diego, CA) and MHC I
(Abcam, Cambridge, MA). After washes with BSA/PBS, cells were
analyzed by a four-color FACSCalibur flow cytometer using
CellQuest software (both from Becton Dickinson, San Jose, CA).
Neural Progenitor Cell Transplantation
NPCs were propagated in growth medium as neurospheres
followed by dissociation and plating on poly-ornithine/laminin-
coated plates. Attached NPCs were passaged once or twice to
obtain evenly distributed monolayer cultures. Cells were then
dissociated with trypsin, washed and prepared as single cell
suspensions for stereotaxic injection as previously described [18].
Cells were suspended in D-PBS with 100 ng/ml FGF at the
concentration of 100 million cells per ml. 100,000 cells were
stereotaxically transplanted into the hippocampus (A/P,
20.22 cm; M/L, +0.14 cm; D/V, 20.26 cm) of mice two months
of age. Two weeks or one month after transplantation, mice were
perfused with 4% paraformaldehyde (Electron Microscopy
Services, Hatfield, PA) in 100 mM phosphate buffer and brains
were removed, post-fixed for 24 hrs in 4% paraformaldehyde, and
then equilibrated in 30% sucrose prior to cryosectioning and
histological evaluation.
Drug Administration
Indomethacin (Sigma-Aldrich, St Louis, MO) and rosiglitazone
(Avandia; GlaxoSmithKline; Research Triangle Park, NC) were
dissolved in strawberry flavored milk at concentrations of 0.2 mg/
ml and 2 mg/ml, respectively. Mice readily consumed the flavored
milk and were dosed with indomethacin (1 mg/kg body weight) or
rosiglitazone (10 mg/kg body weight) once every 12 hrs. Cyclo-
sporine (Bedford laboratories, Bedford, OH) was diluted by saline
to a concentration of 2 mg/ml and 10 mg/kg body weight
administered by i.p. injection every 24 hrs. In addition, mice in
indomethacin- and rosiglitazone-treated groups received daily i.p.
injection of saline and mice in cyclosprine-treated group were
administered with oral flavored milk every 12 hours. Control mice
were administered vehicle only (e.g., oral flavored milk and i.p.
saline injection). Drugs or vehicle were administered two days
before transplant and continued until mice were sacrificed at
48 hrs or 2 wks after transplant.
Tissue Preparation and Immunohistochemistry
Free floating 40 mm coronal brain sections were collected on a
freezing microtome and stored in cryoprotectant buffer at 220uC.
Immunostaining was performed as previously described using the
following primary antibodies and working concentrations. Rat
anti-BrdU ascites (1:1000, Accurate Chemical & Scientific Corp,
Westbury, NY), mouse anti-NeuN (1:500, Chemicon, Billerica,
MA), rabbit anti-NG2 (1:1000, gift from William Stallcup), goat
anti-Dcx (1:500, Santa Cruz Biotechnology, Santa Cruz, CA),
rabbit anti-IBA1 (1:2000, Wako, Richmond, VA), guinea pig anti-
GFAP (1:1000, Advanced Immunochemicals, Long Beach, CA),
rat anti-CD68 (1:500, Serotec, Raleigh, NC), rabbit anti-GFP
(1:1000, Molecular Probes, Carlsbad, CA), rat anti-CD4 (1:500,
eBioscience), rat anti-CD8 (Biotinylated, 1:300, eBioscience) and
mouse anti-MHC I H-2K
b (1:150, BD Biosciences).
Confocal Microscopy
All confocal microscopy was performed using a Zeiss 510 Meta
confocal microscope. Appropriate gain and black level settings
were determined on control tissues stained with secondary
antibodies alone. Upper and lower thresholds were always set
using the range indicator function to minimize data loss through
under or over saturation.
Cell Quantification and Unbiased Stereology
All counts of grafted and endogenous NPCs were limited to the
hippocampal granule cell layer proper and a 50 mm border along
the hilar margin that included the neurogenic subgranular zone.
The counts of infiltrated lymphocytes were limited to the
hippocampus. The proportion of BrdU- or GFP-positive cells
displaying a lineage-specific phenotype was determined by scoring
the co-localization of cellular phenotype markers with GFP or
BrdU using confocal microscopy. Split panel and z-axis orthogonal
projections were used for all counting to minimize false positives.
The counts were performed using multi-channel configuration
with a 40x objective and digital zoom of 2. When possible, 100 or
more BrdU- or GFP-positive cells were scored for each marker per
animal. Each cell was manually examined in its full ‘‘z’’-dimension
and only those cells for which the nucleus was unambiguously
associated with the lineage-specific marker were scored as positive.
The total number of GFP+, BrdU+ or Dcx+ cells per hippocampal
granular cell layer and subgranular zone as well as the number of
CD4+ and CD8+ T cells per hippocampus were determined using
DAB immunodetection and unbiased stereology using Micro-
brightfield Stereo Investigator software. Estimates of cell number
were determined using the di-sector method with Abercrombie
corrections based on average object diameter and section
thickness. All analyses were performed by investigators blinded
to sample identity and treatment group.
Pixel Abundance Analysis
Low magnification images of the DG from every 12
th
consecutively sliced sections were collected on the confocal
microscope with a 10x objective using care to first establish gain
and offset settings that ensured all pixels within any given section
fell within the photomultiplier detection range (no undersaturated
or oversaturated pixels in any tissue section). Images were then
collected from all tissues without altering confocal settings. The
abundance of pixels was analyzed using the program Image J. In
each image, the DG was outlined and the area of the outlined
region was recorded. The background value for each image was
set using the ‘‘threshold’’ function of the program to a level that
would exclude all pixels in control tissues stained with secondary
Mismatch Inhibits Neurogenesis
PLoS ONE | www.plosone.org 9 March 2011 | Volume 6 | Issue 3 | e14787antibody alone. Pixels positive above background for a given
marker were subsequently selected and the area for all positive
pixels was recorded. The relative pixel abundance was indicated
by the area positive above background for each signal normalized
to the isograft group.
Luminex Cytokine Assay
Isogenic or allogeneic NPCs were introduced into the DG of
C57BL/6 mice. Mice were treated daily with indomethacin or
rosiglitazone administered in strawberry flavored milk starting two
days before transplantation until 48 hrs after transplant, when
brains were collected for analysis. Controls were given milk alone.
The mice were transcardially perfused with saline and hippocam-
pal formations were collected and frozen in 280uC. On the day of
Luminex assay, the hippocampi were thawed and lysed in lysis
buffer with sonication. The lysates were clarified by centrifugation
and cell-free protein extracts subjected to Luminex assay of 25-
plex mouse cytokines in technical triplicates per the manufactures
instructions.
Statistics
Differences between more than two groups were tested with
parametrical one-factor analysis of variance (ANOVA), using
Bonferroni-Dunnett corrections as appropriate. Differences be-
tween two groups were tested by using Student’s t test. The level of
significance was set at p,0.05.
Supporting Information
Figure S1 MHC disparity between C57BL/6 and Balb/c mice
induces strong allogeneic responses. (A) Reciprocal heterotopic
cardiac transplantation was performed between Balb/c and
C57BL/6 mice. The cardiac transplants were rapidly rejected
and the time curve of rejection showed similar profile between the
two strains confirming that allo-transplantation between these
strains can be used to model clinical contexts where MHC
mismatch is expected to elicit a strong allograft response. n=4 for
each group. (B) Mixed lymphocyte response. Mitomycin C-treated
C57BL/6 or Balb/c splenocytes were used as stimulator cells and
cultured with isolated C57BL/6 splenocytes. Proliferation was
determined on day 5 by incorporation of 3H thymidine.
Allogeneic Balb/c splenocytes induced strong proliferation of
C57BL/6 splenocytes. n=4.
Found at: doi:10.1371/journal.pone.0014787.s001 (1.05 MB EPS)
Figure S2 MHC and co-stimulatory molecule expression on
NPCs in vitro. (A) NPCs were prepared as a single cell suspension
and stained with either isotype control antibodies (dashed line) or
antibodies recognizing the indicated marker (solid line) and
analyzed by flow cytometry. (B) Allogeneic NPC elicited a
splenocyte response in vitro. Mitomycin C-treated C57BL/6 or
Balb/c NPCs were used as stimulator cells and cultured with
C57BL/6 splenocytes. Proliferation was determined on day 5 by
incorporation of 3H thymidine. (C) MHC and co-stimulatory
molecule expression after cytokine treatment. NPCs were exposed
to the indicated cytokines and then evaluated by flow cytometry
for class I, class II and co-stimulatory molecule expression. Dashed
line, un-stimulated cells; solid line, cytokine stimulated NPCs.
MHC I and MHC II expression on NPCs were mildly upregulated
by TNFa treatment. IFN-c treatment strongly augmented MHC I
and moderately enhanced MHC II expression. However, IL-1b
and IL-6 showed little effect on MHC expression. CD80
expression was enhanced by TNFa, IL-1b, and IFN-c but not
IL-6. Expression of CD40 and CD86 was not detectable on naı ¨ve
NPCs and was not altered by cytokine treatment.
Found at: doi:10.1371/journal.pone.0014787.s002 (3.83 MB EPS)
Figure S3 MHC I expression in vivo. C57BL/6 GFP-positive
NPCs were transplanted into C57BL/6 or Balb/c mice. Two
weeks later, brains were harvested and stained for C57BL/6
strain-specific anti-MHC I (H-2Kb). (A) Naive hippocampal
formations from Balb/c (H-2Kd) mice are negative for H-2Kb.
(B) H-2Kb staining in C57BL/6 mice is readily detected in the
naı ¨ve hippocampus and present at higher levels in cells with
microglial morphology and at low levels in neurons and neuropil.
(C) Graft-specific H-2Kb staining (white) was detected in and
around the transplant site in allogeneic grafts to Balb/c mice.
GFP-positive transplanted cells (green) show much lower staining
(red arrows) than microglial/macrophage-like cells (white arrows).
(D) Isogenic transplants also elicit strong upregulation of H-2Kb
on microglia surrounding the transplant. Contrasting NPCs in the
isograft vs. allograft contexts show no obvious difference in H-2Kb
staining (both are low, red arrows in C and D insets). Green =
GFP; white = H-2Kb. Scale bars = 100 mm.
Found at: doi:10.1371/journal.pone.0014787.s003 (11.36 MB
EPS)
Figure S4 The numbers of CD4+ and CD8+ T cells in
hippocampus do not differ between isograft, allograft and drug-
treated groups. GFP-positive NPCs of C57BL/6 background were
transplanted into C57BL/6 or Balb/c mice given NSAIDS
(indomethacin or rosiglitazone), immunosuppressant CsA or
vehicle starting 2 days prior and continuing for 16 days, at which
time mice were sacrificed and brains harvested. The number of (A)
CD4+ and (B) CD8+ T cells in the hippocampi per mouse was
counted by stereology. Although T cells are present, there were no
statistically significant differences between syngeneic and alloge-
neic transplant groups. n=4–5 animals for each group.
Found at: doi:10.1371/journal.pone.0014787.s004 (0.66 MB EPS)
Figure S5 Intra-hippocampal grafting of allogeneic NPCs does
not prime lymphocyte in host. NPCs on the background of
C57BL/6 or Balb/c were introduced into the DG of Balb/c mice.
One month after transplant, the spleens of host Balb/c mice or
naı ¨ve Balb/c mice that received no graft were removed and the
isolated splenocytes were cultured in vitro with mitomycin C-
treated Balb/c or C57BL/6 splenocytes. 72 hrs later, proliferation
was determined by incorporation of 3H thymidine. Splenocytes
from mice previously transplanted with isogenic vs. allogeneic
NPCs did not differ in the capacity to respond to allogeneic
lymphocyte stimulation, indicating that intra-hippocampal graft-
ing of allogeneic NPCs had not primed the adaptive immune
system in the host. No Transplant = splenocytes from mice that
received no graft; Iso NPC or Allo NPC = splenocytes from mice
that received isogenic or allogeneic NPCs, respectively; Iso spl
stim = mitomycin C-treated Balb/c lymphocytes as isogenic
stimulator cells; Allo spl stim = mitomycin C-treated C57BL/6
lymphocytes as allogeneic stimulator.
Found at: doi:10.1371/journal.pone.0014787.s005 (0.59 MB EPS)
Figure S6 Cytokine expression profile 48 hrs after transplanta-
tion. (A,B) The allograft group showed a trend of upregulation of
IL-17 and IL-3 compared to isograft group, but no significant
difference in the abundance of IFN-c, IL-4, IL-5, IL-6, IL-1a,
MCP-1, VEGF, IL-10 or IL-2. (C) Treatment with indomethacin
or rosiglitazone did not change the production of IFN-c, IL-10,
eotaxin, IL-2, IL-3, IL-4, IL-5, IL-6, IL-1a, VEGF or MCP-1 (#
0.05,p,0.1). n=5–6 for each group.
Found at: doi:10.1371/journal.pone.0014787.s006 (1.01 MB EPS)
Figure S7 Differentiation profiles of C57BL/6 or Balb/c NPCs.
NPCs were plated as monolayers and allowed to differentiate for 5
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staining. Dcx, immature neurons; GFAP, astrocytes; Ng2,
immature oligodendrocytes. n=5.
Found at: doi:10.1371/journal.pone.0014787.s007 (0.67 MB EPS)
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